EP2172201A1 — Pharmaceutical composition for amelioration of lower urinary tract symptom associated with prostatomegaly

USPTO Abstract

The present invention provides a pharmaceutical composition whose active ingredients are (R)-5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl-2-methoxybenzene-1-sulfonamide (tamsulosin), or its pharmaceutically acceptable salt, and (1S)-1-phenyl-1,2,3,4-tetrahydroisoquanoline-2-carboxylic acid (3R)-quinuclidin-3-yl ester (solifenacin), or its pharmaceutically acceptable salt, particularly a pharmaceutical composition for improvement of lower urinary tract symptoms associated with prostatic hypertrophy. It also provides combination use and combination therapy to improve lower urinary tract symptoms associated with prostatic hypertrophy, using tamsulosin, or its pharmaceutically acceptable salt, and solifenacin, or its pharmaceutically acceptable salt.